Company intelligence / Profile preview

Fibrothelium

Aachen, Nordrhein-Westfalen, Germanyfibrothelium.com ↗

Ownership: Private
Development stage: Other

Overview

Fibrothelium has developed a proof-of-concept for biotechnological production of proprietary silk proteins, demonstrating their potential use in biomedical products and medical devices. Their materials are biodegradable, non-toxic, and environmentally friendly. The company’s focus is on sustainable implants that dissolve when no longer needed.

Therapeutic areas: Other
Modalities: ProteinHydrogel-based drug delivery therapyScaffold
Industry: Implantable Medical Devices

Partnerships

RWTH Aachen UniversityBIOMAN4R2 project/funding program support

Beyond the preview

Go deeper on Fibrothelium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrothelium.

Explore the full profile